Patrick A. Baeuerle

C4 Therapeutics (United States) — United States

Medicine · Health Sciences

122h-index64.2kcitations436works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(188), CAR-T cell therapy research(141), NF-κB Signaling Pathways(92), Immune Response and Inflammation(55), Immunotherapy and Immune Responses(52)

Publications436 total

Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics
Journal for ImmunoTherapy of Cancer·2026Open Access
973 Identification of MUC13xMSLN as a novel tumor-specific antigen pair for AND-gated T cell engagers in colorectal cancer
Regular and Young Investigator Award Abstracts·2025Open Access
344 Safety and efficacy of targeting the p14ARF tumor suppressor using TCR T-cell therapy
Regular and Young Investigator Award Abstracts·2025Open Access
345 Discovery and characterization of human T cell receptors that recognize tumor-associated antigens derived from tumor suppressors p16INK4A and p14ARF
Regular and Young Investigator Award Abstracts·2025Open Access
Umprogrammierte T-Zellen zur Behandlung der rheumatoiden Arthritis
rheuma plus·2025Open Access
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
Journal for ImmunoTherapy of Cancer·2025· 5 citedOpen Access
Intratumoral injection and retention hold promise to improve cytokine therapies for cancer
Frontiers in Oncology·2024· 5 citedOpen Access
Supplementary Figure S6 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Data from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S9 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S11 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S2 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S10 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S3 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Table S2 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S5 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S13 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Methods File S1 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S10 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
Supplementary Figure S15 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
2024Open Access
page 1 of 22Next →

Frequent Co-authors

Peter Kufer(8), Ralf Schreck(7), Ralf C. Bargou(7), Gerhard Zugmaier(5), Matthias Klinger(5), Andreas Viardot(5), Dirk Nagorsen(5), Hermann Einsele(4), Margit Schmidt(4), Gert Riethmüller(4), Christian Kaltschmidt(4), Thomas Henkel(3), David Baltimore(3), Mariele Goebeler(3), Christian Brandl(3), Andreas Wolf(3), Carsten Reinhardt(3), E. Britta-Mareen Traenckner(3), Heike L. Pahl(3), Nicola Gökbuget(3)